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Molecular and cellular mechanisms of aging 
in hematopoietic stem cells and their niches
Lei Zhang1, Ryan Mack1, Peter Breslin1,2 and Jiwang Zhang1,3* 
Abstract 
Aging drives the genetic and epigenetic changes that result in a decline in hematopoietic stem cell (HSC) functioning. 
Such changes lead to aging-related hematopoietic/immune impairments and hematopoietic disorders. Understand-
ing how such changes are initiated and how they progress will help in the development of medications that could 
improve the quality life for the elderly and to treat and possibly prevent aging-related hematopoietic diseases. Here, 
we review the most recent advances in research into HSC aging and discuss the role of HSC-intrinsic events, as well as 
those that relate to the aging bone marrow niche microenvironment in the overall processes of HSC aging. In addi-
tion, we discuss the potential mechanisms by which HSC aging is regulated.
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Background
The primary functions of blood cells are transporting 
oxygen to tissues by red blood cells (RBCs), antagoniz-
ing infections caused by pathogenic agents (macrophages 
and neutrophils), maintaining coagulatory hemosta-
sis (platelets), and confronting and responding adap-
tively to internal and external antigenic affronts (T and 
B lymphocyte-mediated immune defense). In the adult 
human, ~ 4–5 × 1011  blood cells are lost every day due 
to cellular aging or damage. To replenish the loss of 
blood cells, approximately the same numbers of blood 
cells must be produced from bone marrow (BM) hemat-
opoietic progenitors daily [1–3]. Normal homeostatic 
multi-lineage blood cell regeneration, including immune-
related tissue, is primarily maintained through multipo-
tent hematopoietic progenitors (MPPs), which become 
exhausted over time, whereas lifetime hematopoiesis and 
immunity are maintained by self-renewable hematopoi-
etic stem cells (HSCs) that are localized within special-
ized BM microenvironments called HSC niches [4–9].
Like most other tissue-specific stem cells, HSCs are 
vulnerable to aging-related stress and gradually lose their 
self-renewal and hematopoietic regenerative capacities 
(HRC) [10–12]. The process of aging in HSCs is driven 
by both cell-intrinsic and extrinsic factors, which lead 
to a reduction in blood cell production and impairment 
of immune system function [13–16]. Consequently, 
elderly populations experience higher incidences of ane-
mia, arterial thrombosis, and myeloid and lymphoid 
malignancies (such as age-related clonal hematopoiesis, 
myelodysplastic syndromes, acute myeloid leukemia, 
chronic lymphocytic leukemia, multiple myeloma and 
non-Hodgkin’s lymphoma) [17–19]. In addition, this 
population may experience declining adaptive immunity, 
autoimmunity, vaccine failure, and experience increased 
innate immune-inflammation and susceptibility to infec-
tious diseases [20–23]. Thus, a more in-depth elucidation 
of the molecular and cellular mechanisms by which HSC 
aging are inter-regulated will not only help in the devel-
opment of medications for treating and preventing age-
related hematopoietic and immune disorders, but also 
provide strategies to advance the quality of life of elderly 
populations by reducing the burden of dysfunctional 
hematopoiesis and immunity due to aging [24–26].
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Changes in elderly human, monkey, and mouse HSCs 
compared to younger adults include: (1) increased num-
bers; (2) compromised HRC; (3) skewed myeloid differ-
entiation at the expense of T/B lymphocytes; [27–31] (4) 
expansion of functionally defective HSCs; and (5) accu-
mulation of clonal hematopoiesis, specifically, genetically 
mutant HSCs, due to the selective expansion of age-asso-
ciated somatic mutant HSCs [10, 11, 13, 32–34]. All of 
these changes explain the aging-related alterations seen 
in peripheral blood (PB) and tissues, including: (1) atten-
uated blood cell regeneration in response to radiation or 
chemical-induced BM damage; (2) increased percentages 
of granulocytes and monocytes, which is always accom-
panied by a reduced percentage of T/B lymphocytes and 
impaired adaptive immunity; (3) reduced anti-infective 
activity of neutrophils; and (4) slightly reduced RBC and 
platelet numbers [16, 35, 36]. It needs to be mentioned 
that all these conclusions regarding the aging of HSCs 
were obtained from studies of mouse models, primarily 
owing to the availability of relatively specific cell surface 
markers that have permitted superior purification and 
functional assessment of HSC biology. Nevertheless, 
almost all of these conclusions have been verified in other 
species, suggesting conserved mechanisms of HSC aging 
[37]. Thus, mouse models provide reliable tools to study 
the parameters of aging in human HSCs, as age-related 
milestones in the murine hematopoietic system reflect 
those of humans. C57BL6 mice are commonly used to 
study HSCs. It is commonly accepted that 2–6 month-old 
mice are young adults, which correspond to 20–39 year-
old humans. Mice which are > 20 months-old are consid-
ered to be aged mice, corresponding to 65–70  year-old 
humans. Almost all conclusions of aged-HSCs from 
previous studies were acquired by comparing HSCs col-
lected from > 20 month-old mice to HSCs collected from 
2–5 month-old mice. We will focus on the data obtained 
from mouse models in this review.
Can the same markers for analysis of young HSCs 
be used for aged HSCs?
Significant advances have been made during the past 4 
decades in the identification and purification of HSCs in 
mice, specifically in C57Bl6 mice. HSCs are fundamen-
tally characterized by specialized molecular markers for 
purification and serial transplantation to determine their 
capacity to: (1) generate long-term reconstitution of all 
blood lineages (multipotency) in irradiated recipient ani-
mals; and (2) produce multipotent HSCs themselves in a 
process called self-renewal [38–40]. However, all markers 
currently in use for HSC analysis were developed using 
young HSCs, and we should first determine whether 
these markers can be reliably used when studying old 
HSCs.
Development of markers for HSC analysis and purification
Lineage−Sca1+c-Kit+ (LSK) was the first identified con-
stellation of markers for HSC analysis [41], which label 
cells containing HSCs and all 4 types of MPPs (MPP1, 
2, 3 and 4) [42, 43]. These HSCs give rise to MPPs, 
which in turn produce myeloid or lymphoid commit-
ted progenitors that subsequently produce all PB and 
immune cells. Although MPPs have short-term multi-
lineage hematopoietic reconstitutive activity (ST-HRC), 
each MPP type exhibits lineage bias, suggesting that 
they possess a lineage-primed feature. Only ~ 2% of LSK 
cells have LT-HRC, suggesting that approximately 1 in 
50 LSK cells are functional HSCs (fHSCs) [44]. Many 
different combinations of markers have been devel-
oped to further separate HSCs from MPPs by the addi-
tion of more markers in the staining panel for LSK cells 
in order to increase the purity of HSCs. For example, 
the addition of Flk2 and CD34 permitted Weismann’s 
lab to identify HSCs within the  LSKCD34−flt3− popu-
lation [45–47]. By incorporating CD48 and CD150, 
Morrison’s lab was able to identify HSCs within the 
 LSKCD48−CD150+ population [48]. By the incorpora-
tion of EPCR, Mulligan’s lab identified HSCs within the 
 LSKCD34−flt3−EPCR+  population [49, 50]. The use of 
Hoechst 33342 staining gave Goodell’s lab the ability to 
identify HSCs within a side population, (SP)-LSK cells 
[51, 52]. Such combinations of markers identified par-
ticular HSCs called phenotypic HSCs (pHSCs), which 
are enriched among fHSCs at 20%–40% purity as vali-
dated by serial dilution-competitive transplantation 
assays. HSCs identified by these different combina-
tions of markers show 70–80% overlap, suggesting that 
in addition to marking fHSCs, each panel of markers 
also identifies a distinct subset of MPPs. For example, 
SP-LSK  cells are 100%  CD34−/lowFlk-2−CD48−, and 
90% with  EPCR+ which can be further separated into 
 CD150hi,  CD150lo and  CD150− sub-populations [53]. 
Thus, further combinations of these markers allowed 
for increased purity of HSCs [42, 43]. In addition, dur-
ing the past several years, many HSC-specific reporter 
mouse lines were generated by inserting a fluorescent 
protein gene under the control of HSC-specific gene 
regulators such as Hoxb5-mcherry [54], Fgd5-ZsGr, 
[55] α-catulin-GFP, [56] Tie2-eGFP [57], and Pdzk1ip1-
GFP [9]. In these reporter lines, the fluorescent protein 
specifically marks all fHSCs in young mice, which com-
prise 10–35% of pHSCs. Transplantation studies sug-
gested that fluorescent-protein+ LSK cells are nearly 
100% pure fHSCs that have long-term multi-lineage 
(LT-ML) HRC. Thus, these HSC reporter mouse strains 
provide useful, reliable tools for HSC studies.
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Increase in phenotypic HSC number and decrease 
in regenerative capacity during aging
Compared to young adult mice, elderly mice dis-
play a significant increase in the number of pHSCs 
(~ 17-fold for  CD34− LSK cells, [27] ~ 15-fold for 
LSK-CD48−CD150+, ~ 12-fold for  CD34−LSK-CD48−​
CD150+EPCR+, [58] ~ 5-fold for SP-LSK [52  ]
and ~ 10-fold for  CD34−LSK-CD48−CD150+FLK2−) 
[59]. Nevertheless, transplantation studies suggested 
that the LT-ML HRC of the unpurified BM cells iso-
lated from old mice is increased by only ~ twofold com-
pared to young mice, which is consistent with the ~ 2-fold 
increase in functional HSCs determined by standard 
serial dilution and competitive transplantation assays [27, 
60]. Interestingly, compared to young adults, the 2-fold 
increased LT-HRC in old BM cells is better correlated to 
the ~ 1.9-fold increase in LSK cells [27, 61, 62]. This sug-
gests that all LT-ML HRC cells are enriched within the 
LSK cell population. However, a 2-fold increase in fHSCs 
is not consistent with the 10–17-fold increase in pHSCs. 
Nevertheless, all fHSCs that have LT-ML HRC are still 
within the pHSC population among old mice, regard-
less of which panel of markers was used, suggesting 
that fHSCs are enriched within the pHSC population in 
old mice. The dramatic increase in pHSCs in old mice 
was confirmed by studies of HSC reporter mice such as 
Hoxb5-mCherry, Fgd5-ZsGr, Pdzk1ip1-GFP, and Gprc5c-
EGFP [54–56, 63]. The percentage of  fluorescence+ HSCs 
is consistently increased in pHSCs of old mice (65–80%) 
compared to the percentage of  fluorescence+ HSCs in 
young animals (10–35%) in these reporter lines. Thus, 
the number of  fluorescence+ HSCs is increased 25–50-
fold in old mice compared to young mice. (Fig. 1a). The 
increased pHSCs and  fluorescence+ HSCs in old mice are 
not the result of the induction of HSC markers in MPPs 
by inflammatory cytokines in the BM environment of 
older animals, because the expression of the fluorescent 
protein in the reporter mice cannot be induced by any of 
the inflammatory cytokines. Therefore, increased pHSCs 
and  fluorescence+ HSCs in old animals are unlikely to be 
due to increased contamination of MPPs. The markers 
that have been used to identify HSCs in young adults can 
still reliably label HSCs in the elderly.
Two potential mechanisms explain the inconsistency 
of pHSCs,  fluorescence+ HSCs and fHSCs in old ani-
mals are the following: (1) if the HSCs are functionally 
MPPs
pHSCs flu+ HSCs
Young adult                                       Elderly
LSKs   ~1.9 fold 
pHSCs 10-17 fold 
flu+ HSCs 20-50 fold 
pHSCs/LSK:            ~5%                                                   25-30% 
flu+ HSCs/pHSCs: 10-35%                                                65-80% 
MPPs MkP
? 




Fig. 1 Aging-related changes in pHSCs and  flu+ HSCs. a Compared to young mice, LSK cells are increased by 1.9-fold in BM of old mouse pHSCs. 
However, HSCs and  flu+HSCs in BM of old mice are expanded by 10–17-fold and 20–50-fold, respectively, owing to the dramatically increased 
ratios of pHSCs/LSK and  flu+HSCs/pHSCs. b The reduction in ratios of pHSCs/LSK and  flu+HSCs/pHSCs in old mice might be due to the reduced 
production of MPPs and/or increased production of MKPs or other committed progenitors which bypass the MPP stage
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homogeneous, as suggested in the early HSC hierarchi-
cal model, then the LT-ML HRC of almost all individual 
HSCs should be attenuated in older mice; however, (2) if 
the HSCs are functionally heterogeneous, then signifi-
cantly more functionally defective HSCs should accumu-
late in old animals with only a proportion of HSCs still 
maintaining LT-ML HRC. Almost all recent studies sup-
port the second mechanism. The significant increase in 
the percentage of pHSCs and  fluorescence+ HSCs within 
the LSK population in old mice is due to differentiation 
defects in aged HSCs, which produce fewer MPPs com-
pared to young HSCs. These defects could be either dif-
ferentiation inhibition or differentiation to committed 
progenitors, such as megakaryocyte progenitors (MkPs) 
that bypass the MPP stage (Fig. 2).
Increase in lineage‑biased HSCs and functionally 
defective HSCs in older animals
Single cell studies demonstrated that HSCs are function-
ally heterogeneous in terms of both mature cell produc-
tion and the durability of self-renewal. Compared to 
young HSCs, such heterogeneity is significantly amplified 
in aged HSCs as determined by in  vitro single cell cul-
turing, in vivo single cell transplantation, and single cell 
RNA sequencing studies [31, 64–69].
Significant increase in lineage‑biased HSCs and functional 
defects in HSCs with subtle increase in balanced HSCs 
in old mice
In in vitro stromal co-cultures, [27, 58] the behaviors of 
HSCs are not the same in terms of their colony-forming 
efficiency, cellular components or colony sizes. Most 
young HSCs generate large, multi-lineage mixed colo-
nies, while only a small proportion of old HSCs are able 
to generate such large multi-lineage clones. Aged HSCs 
showed reduced clonogenic efficiency, delayed prolifera-
tion and reduced multipotency with myeloid lineage bias 
as demonstrated by reduced numbers of colonies, longer 
times to form colonies, and more small-sized uni-lineage 
or oligo-lineage colonies dominated by granulocytes and 
monocytes. Such heterogeneous features of HSCs were 
confirmed by single-cell transplantation studies. Based 
on myeloid and lymphoid reconstitution ratios, Eaves’ 
lab classified the LT-HSCs into α- and β- subtypes [66, 
70]. Both α- and β- subtypes have robust self-renewal 
activity and LT-HRC. The α-HSCs are myeloid-biased 
(My-bi) HSCs that produce blood cells with a lower lym-
phoid/myeloid ratio due to an inherited deficiency in 
lymphocyte differentiation [70]. β-HSCs are balanced 
(Bala)-HSCs, which produce relatively balanced ratios 
of lymphocytes to myeloid cells. The number of α-HSCs 
and β-HSCs dynamically changes during development 






IT-HSCs     ~9-fold 
ST-HSCs   ~10-fold 
IT/ST-Lineage restricted progenitors   ~10-20-fold 
Latent HSCs  LT-HSCs  
Defective 
HSCs
(∼82 per 106 BM cells) 






Unidentified cells  ~20-fold 
pHSCs 
Young adult                                   Elderly 
Fig. 2 Aging-related changes in fHSCs. Single-cell transplantation studies demonstrate a 2–3-fold expansion of Bala-HSCs, suggesting that 
functionally normal HSCs exist in aged mice. A significant number of latent HSCs can be detected only in elderly. In addition, more defective HSCs 
and NR-HSCs can be detected in older mice
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significantly increased in old animals, whereas β-HSCs 
are slightly increased [70].
The expression of several megakaryocyte–platelet 
markers, such as CD150 [31], CD41 [71], CD61 [72] 
and Vwf, [68] are increased in aged HSCs. In addition, 
Neogenin-1 (NEO1), a multifunctional transmembrane 
receptor, is also increased in aged HSCs [59]. By adding 
such markers to the well-defined pHSC panels, along 
with transplantation functional studies, several labs were 
able to largely isolate My-bi HSCs  (CD150hi,  CD41+, 
 CD61+, c-Kithi,  Vwfint or  Neo1+) from Bala-HSCs 
 (CD150lo,  CD41−,  CD61−, c-KitInt,  Vwflo or  Neo1−) [71, 
73]. As is the case with α- and β- HSCs, My-bi HSCs are 
significantly expanded in older animals, whereas Bala-
HSCs are slightly increased [70]. However, all these stud-
ies used antibodies against the CD45 isoforms CD45.1 
and CD45.2 to distinguish blood cells derived from test-
ing HSCs from blood cells derived from competitor cells 
and host cells. Because CD45 cannot be detected in both 
RBCs and platelets, all these studies only examined gran-
ulocyte, monocyte and lymphocyte contributions to total 
HSCs but failed to detect RBC and platelet contributions.
By using HSCs isolated from fluorescent  protein+ mice, 
Jacobsen’s lab identified platelet-biased (Plt-bi) HSCs. 
Such HSCs express high levels of Vwf  (Vwfhi), which 
generate either platelets alone or platelets with minimal 
RBCs and granulocytes. The existence of Plt-bi HSCs was 
verified by both single-cell RNAseq assay and noninva-
sive in situ fate mapping methods in unperturbed mouse 
hematopoiesis [4, 5, 7, 74], suggesting that Plt-bi HSCs 
are a feature of native hematopoiesis [74, 48, 49]. These 
studies demonstrated that Plt-bi HSCs represent a pro-
portion of My-bi HSCs. As is the case with My-bi HSCs, 
Plt-bi HSCs are also significantly expanded in old mice. 
Studies suggested that at a single-cell level, both Plt-Bi 
HSC and My-bi HSC produce a lower output of mature 
blood cells than Bala-HSCs in primary transplantation 
recipients. However, serial transplantation studies sug-
gest that some Plt-bi HSCs and My-bi HSCs have higher 
self-renewal capacity and are able to generate Bala-HSCs 
in the recipient BM [75]. This suggests that Plt-bi HSCs 
and My-bi HSCs are at the apex of the HSC hierarchy, 
upstream of Bala-HSCs. However, due to the lack of reli-
able assays to further separate Plt-bi HSCs from My-bi 
HSCs, the exact relationship between Plt-bi HSCs and 
My-bi HSCs has not been delineated. Further study will 
need to determine whether Plt-bi HSCs are at the apex 
of the HSC-hierarchy, upstream of both My-bi HSCs and 
Bala-HSCs, or whether Plt-bi HSCs and My-bi HSCs are 
at the same level in the HSC hierarchy.
By doing a more detailed analysis of a relatively large 
series of single HSC transplantations, Yamamoto et  al. 
found that Bala-HSCs are expanded 3-fold in old mice, 
while My-bi/Plt-bi HSCs are expanded > 60 fold. Many 
of these My-bi/Plt-bi HSCs displayed multipotent output 
(were able to produce all 5 blood cell lineages) in second-
ary recipients, suggesting a latent type of HSC (also called 
MyRP). Such latent HSCs can be identified in BM of old 
mice but not in young mice [76]. In addition, significantly 
more functionally defective HSCs, such as intermediate-
term and short-term HSCs, were detected in old mice. 
Furthermore, significantly more non-hematopoietic 
reconstituting (NR)-HSCs are detected in old mice. Such 
NR-HSCs failed to reconstitute any of the 5 lineages of 
blood cells in recipient mice, probably due to a failure of 
survival, homing or proliferation during transplantation. 
There is also the possibility that some of the NR-HSCs 
produce innate immune cells that are localized in tissues 
and cannot be detected using current strategies. (Fig. 3).
Taken together, HSCs are highly heterogeneous. The 
increased number of pHSCs in old mice is primarily 
due to a dramatic increase in My-bi HSCs, Plt-bi HSCs, 
latent-HSCs and NR-HSCs, with a subtle increase in 
Bala-HSCs. Importantly, the Plt-bi, My-bi and latent 
HSCs are less effective in LT-HRC compared to Bala-
HSCs, as demonstrated in primary recipients, probably 
due to their bypassing of the intermediate steps in the 
generation of mature progeny. Nevertheless, these line-
age-biased HSCs are true fHSCs, not short-term HSCs 
or MPPs, because they are able to produce multi-lineage 
blood cells in secondary transplant recipients. It also sug-
gests that the ineffective HRC of some of lineage-biased 
HSCs is induced by BM environmental influences in old 
mice, which can be reversed when transplanted into a 
younger BM microenvironment. Functionally defective, 
aged HSCs are either dormant or lineage-primed, and 
serial transplantation will be required in order to thor-
oughly study HSC aging [75].
What is the origin of lineage‑biased HSCs and functionally 
defective HSCs in old mice?
Increased NR-HSCs in aged mice can be explained by 
an increase in apoptosis, senescence or homing defects 
due to the accumulation of DNA damage as well as mito-
chondria and/or other key cellular organelles becoming 
defective. However, the precise origin of My-bi and Plt-bi 
HSCs in old mice is still being debated. Two hypotheses 
have been proposed to explain the origin of My-HSCs 
and Plt-Bi HSCs: (1) they might arise from the cell-intrin-
sic transition of Bala-HSCs to lineage-biased HSCs[29, 
31, 77], or (2) they may be generated from the clonal 
expansion of preexisting fractions of lineage-biased HSCs 
[72, 78, 79] (Fig. 4).
By tracking the mitotic history of HSCs during physi-
ologic aging using H2B-GFP+ long-term-label retaining 
(LR) assay, Trumpp’s lab found that HSCs might only 
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divide 5 times during the lifespan of a mouse [42]. Dur-
ing each successive division, HSCs progressively acquire 
myeloid-primed features at the expense of lymphoid 
differentiation potential and self-renewal capacity [80]. 
Moore’s lab demonstrated that HSCs undergo sym-
metric division in the BM niche and gradually acquire 
My-bi characteristics, which is always companied by an 
irreversible reduction in self-renewal capacity. The LR-
HSCs (≤ 4 divisions) in old mice contain only fHSCs 
which still preserve multipotency (with a myeloid bias) 
and self-renewal potential, whereas the H2B-GFP− non-
LR-HSCs (> 4 divisions) represent functionally defective 
HSCs, intermediate HSCs and lineage-restricted pro-
genitors. Thus, non-LR-HSCs have minimal self-renewal 
and restricted regenerative capacity [81, 82]. Szade’s lab 
found that Neo1 is a better marker for separating My-bi 
HSCs from Bala-HSCs.  Neo1−Hoxb5+  Bala-HSCs give 
rise to  Neo1+Hoxb5+  My-bi HSCs but the reverse 
transition is rarely observed. Using a paired daughter-
cell assay (PDA), Nakauchi’s lab found that Bala-HSCs 






≤ 4 divisions: My/Plt-HSCs
>4 divisions: My/Plt-MPPs
Young                                    Old 
Bala-HSCs
≤ 4 divisions >4 divisions
a
b 
≤ 4 divisions >4 divisions
DR-HSCs from fetal?
Fig. 3 Models for aging-driven expansion of Plt/My-bi HSCs. Two models were proposed to explain the origin of Plt/My-bi HSCs. a. The Plt/My-bi 




Asymmetric division Symmetric division
Combined model
Fig. 4 Models for aging-related changes in symmetric and asymmetric division in HSCs. a Asymmetric division of HSCs helps to maintain functional 
HSC numbers by distributing stemness factors to one of the daughter cells and differentiation factors to the other. b Symmetric division of HSCs 
leads to a gradual dilution of their stemness during each division until it is practically absent. c More HSCs in young mice undergo asymmetric 
division; they switch to symmetric division during aging
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asymmetrically give rise to Bala-HSCs and Plt-bi HSCs 
(MkRPs) or My-bi HSCs, during in vitro short-term incu-
bation [67]. These studies suggest that the My-bi HSCs 
are produced by Bala-HSCs and these undergo irrevers-
ible loss of stemness (self-renewal and multipotency) 
after the fourth division. However, serial transplanta-
tion studies suggest that a proportion of Plt-bi HSCs and 
My-bi HSCs are latent HSCs which have LT-ML HRC in 
secondary transplantation. Although these latent HSCs 
are only able to reconstitute very low levels of platelets, 
RBCs and granulocytes/monocytes in primary recipients, 
they have significantly strong self-renewal capacity and 
are able to reconstitute the 5 lineages of hematopoiesis 
in secondary recipients [76], suggesting that the lineage-
biased feature of aged HSCs is reversible. This conclu-
sion was supported by Jacobsen’s lab, which showed that 
Plt-bi HSCs are located at the apex of the HSC hierar-
chy and give rise to Bala-HSCs during transplantation 
[83]. Such a discrepancy among the conclusions of these 
studies is primarily due to the different research strate-
gies that were employed. The LR-HSCs in Moore’s stud-
ies might contain all real fHSCs including Bala-, My-bi 
and Plt-bi HSCs as defined by Nakauchi’s lab, whereas 
the non-LR-HSCs only contain ST-HSCs, IT-HSCs and 
lineage-restricted progenitors. The  Neo1−Hoxb5+ HSCs 
in Szade’s study are not pure Bala-HSCs, because they 
express myeloid differentiation-related genes compared 
to young HSCs. Thus, reliable markers are required to 
faithfully distinguish Bala-, My-bi- and Plt-bi-HSCs for 
determining the relationship of these 3 types of HSCs in 
the hematopoietic hierarchy. Such information is critical 
not only for a better understanding of the mechanisms 
of HSC aging and hematopoietic diseases, but also for 
improving methods for effective ex vivo HSC expansion.
Studies from several other groups suggested that aging 
drives the change of the clonal composition of the HSC 
compartment but not individual HSCs. My-bi and Plt-
bi- HSCs already exist in young adults and are expanded 
during aging. The biological and functional similar-
ity of My-bi and Plt-bi HSCs from young and old mice 
suggest that a clonal expansion of the pre-existing line-
age-biased HSCs occurs [67]. These pre-existing line-
age-biased HSCs in young adults might be residual fetal 
HSCs which have been established as developmentally 
restricted HSCs in neonatal BM. The developmentally 
restricted HSCs in neonatal BM most likely develop from 
early erythromyeloid progenitors (EMPs) generated dur-
ing the secondary wave of embryonic hematopoiesis in 
the yolk sac, because they continuously produce B1 and 
γδT innate immune cells [84, 85]. Future studies need to 
address whether these pre-existing My-bi HSCs and Plt-
bi HSCs in young adults develop from yolk sac EMPs or 
from AGM-definitive HSCs [86, 87].
Cell‑intrinsic mechanism of HSC aging
Increased stress due to cell replication, redox stress, 
mitochondrial dysfunction, and DNA damage have been 
defined as hallmarks of HSC aging. Studies have sug-
gested that HSC-intrinsic changes are induced by prolif-
eration. However, whether HSC-intrinsic changes during 
aging are primarily induced by BM niche changes or are 
due to niche-independent changes needs to be investi-
gated in the future. In addition, whether aged HSCs regu-
late the aging of their niches must be evaluated [88].
Proliferation drives HSC aging
In the adult, almost all HSCs are quiescent with respect 
to the cell cycle (maintained in  G0 phase), with only 
a small proportion of HSCs (< 5%) at any point in time 
entering into the cell cycle for hematopoietic regenera-
tion. Early studies suggested that HSCs divide on average 
every 57 days in mice and once every 18 years in humans 
[89]. By tracking the cell division-related fluorescence 
dilution of fluorescent protein-labeled HSCs, Trumpp’s 
and Hock’s groups found that quiescent mouse HSCs 
take an average of 128 (56–145) days for one division 
under normal physiological circumstances [42, 90]. Thus, 
dormant HSCs divide approximately 5 times over the 
course of mouse’s lifetime. Recent studies suggested that 
the self-renewal and LT-ML HRC of HSCs are negatively 
correlated to their divisional history in normal physiolog-
ical hematopoiesis [82, 91–93]. Therefore, it is speculated 
that the major driver of HSC aging is proliferation. Sus-
taining the quiescent state is pivotal for preserving the 
stemness of adult HSCs by maintaining their low meta-
bolic activity, epigenetic landscape and genomic stability. 
The increase in HSC number in the elderly is due to the 
expansion of functionally attenuated HSCs [23]. Several 
potential mechanisms were proposed to explain how cell 
divisions attenuate HSC activity, including the induction 
of replicative stress, DNA damage, epigenetic landscape 
changes, metabolic stress and shorting telomere length 
[94–96].
Both symmetric and asymmetric divisions have been 
proposed for HSC proliferation. In the symmetric divi-
sion model, HSCs equally distribute their organelles 
and molecular components into the two daughter cells. 
In most cases, HSCs undergoing symmetric division 
will undergo dilution of their stemness and accumulate 
stress-related damage during each division, eventually 
becoming exhausted after 4–5 divisions. Only in cer-
tain situations, such as fetal HSC development, are both 
daughter cells able to maintain self-renewal and multi-
potency leading to an expansion in their number. How-
ever, in the asymmetric division model, HSCs unevenly 
distribute their organelles and molecular components, 
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leading to cellular polarity. The daughter cells which 
receive healthy organelles, such as mitochondria and 
lysosomes, [97–100] and self-renewal factors, such as 
Cdc42, tubulin and  H3K36Ac, will maintain HSC activity, 
[11, 30, 101–103] while daughter cells receiving impaired 
organelles and differentiation factors will lose HSC activ-
ity. Thus, HSCs which undergo asymmetric division 
should be maintained in the HSC pool permanently. The 
progressive loss of cellular polarity in aged HSCs suggests 
that more young HSCs undergo asymmetric division 
and switch to symmetric division in aged HSCs [71, 72]. 
The increased number of HSCs in old mice might be a 
compensatory mechanism to overcome their loss of HSC 
function due to an increase in the frequency of symmet-
ric cell divisions during aging [23] (Fig. 5).
However, some Plt-bi and My-bi HSCs from older ani-
mals have more robust self-renewal capacity and can 
generate Bala-HSCs in transplantation recipients, sug-
gesting that lineage determination can be uncoupled 
from self-renewal [76, 83, 104]. It was found that HSCs 
can differentiate into restricted progenitors (including 
common myeloid, megakaryocyte–erythroid and pre-
megakaryocyte progenitors) without undergoing cell 
division and even before entering S phase of the cell cycle 
[105]. Therefore, HSC fate decisions can be also uncou-
pled from physical cell division [105]. The exact mecha-
nism by which proliferation induces HSC aging remains 
unknown.
DNA damage and genetic mutations in aging HSCs
Compared to proliferative progenitors which use an 
error-free homologous recombination (HR) pathway for 
DNA damage repair, quiescent HSCs are particularly 
vulnerable to DNA damage due to their preferential use 
of the error-prone non-homologous end joining (NHEJ) 
repair pathway [106]. Approximately, a 2- to 3-fold 
increase in accumulated DNA damage in aged HSCs 
has been suggested by staining of γH2AX foci, alkaline 
comet assay, DNA mutation frequency, and LOH assay 
[77, 94, 107, 108], which explains the acquired mutations, 
aging-related clonal hematopoiesis and increased risk 
of myeloid malignancies in the elderly [109–111]. The 
driver role of DNA damage in HSC aging has been sug-
gested by the premature age-related phenotype of HSCs 
isolated from mice deficient in DNA repair pathway com-
ponents [77, 112–114]. DNA damage and mutations in 
HSCs might be generated by errors in DNA synthesis 




























































Fig. 5 BM HSC niches. Endosteal/arteriolar niches are localized close to the endosteal region of BM, which are populated by  CD31hiEmcnhi type-H 
ECs and osteogenic-biased MSC-SCs in the arteriolar capillaries at the distal end of the arterial network (transition zone vessels have substantial 
branching). Sinusoid niches are localized to the central region of BM and are composed of type-L ECs and adipogenic-biased MSC-SCs. In addition, 
MKs, Mφ and Treg cells also function as niche cells to maintain HSC quiescence, retain HSCs within their BM niche, and to protect HSCs from 
immune attack. In addition, the adrenergic sympathetic nerve also functions as niche component for HSCs by regulating HSC relocation between 
niches
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by endogenous metabolic factors, such as increased ROS 
levels or by environmental stresses [115]. DNA damage 
diminishes HSC function by inducing a DNA damage-
repair response through stimulation of cell cycle check-
point activation, CD53-p21-mediated cell cycle arrest, 
 p16Ink [4]-mediated senescence and p53-PUMA-medi-
ated apoptosis [77, 106, 116]. However, cell-intrinsic fac-
tors that cause increased DNA damage in aged HSCs are 
controversial. Weissman’s lab found that a distinct set of 
DNA damage repair proteins are reduced in aged HSCs 
compared to young HSCs [108]. However, Passegué’s lab 
found an increased number of errors in DNA replication 
in aged HSCs [94]. Geiger’s lab demonstrated that young 
and aged HSCs are comparable in DNA damage repair, 
cell-cycle checkpoint activation and apoptosis, suggest-
ing that increased DNA damage and mutations in aged 
HSCs are more likely to accumulate gradually [117].
Replication stress and ribosome biosynthetic stress in HSC 
aging
Passegué’s lab found that the increased number of 
γH2AX foci in aged HSCs is not associated with DNA 
damage due to the lack of co-localization of γH2AX foci 
with DNA damage proteins (53BP1 and pCHK1) or DNA 
fragmentation (poly-ADP-ribose (PAR) and TUNEL 
staining), suggesting that such foci are DNA-damage 
independent. However, the increase in γH2AX foci is 
strongly associated with increased staining of the sin-
gle-stranded DNA binding proteins RPA and ATRIP in 
proliferative aged HSCs, suggesting a stalled and/or col-
lapsed replication fork-associated γH2AX. The impaired 
replication of old HSCs is associated with reduced 
expression of mini-chromosome maintenance (MCM) 
helicase components. They also observed a long-term 
persistence of nucleolar γH2AX in quiescent, old HSCs, 
leading to reduced expression of rRNA owing to ineffec-
tive H2AX dephosphorylation due to mislocalization of 
PP4c. Impaired replication induces the activation of rep-
licative stress in proliferative, aged HSCs and the reduced 
rRNA expression induces ribosomal biosynthetic stress 
in quiescent aged HSCs. This study suggests that repli-
cative stress and ribosomal stress are potent drivers of a 
functional decline in aged HSCs [94]. Consistent with the 
results of this study, it was found that ribosomal stress is 
one of the key mechanisms common to diseases related 
to BM failure [118, 119].
Mitochondrial and metabolic stress in aging HSCs
Although quiescent HSCs have a relatively high con-
centration of mitochondria compared to hematopoi-
etic progenitors, mitochondria in HSCs are relatively 
inactive (morphologically small, round and polarized 
with low numbers of swollen cristae) [120, 121]. In 
contrast to hematopoietic progenitors in which mito-
chondria primarily use the oxidative phosphorylation 
(OXPHOS) mechanism to generate energy, HSCs use 
mitochondria-independent glycolysis to satisfy their 
energy requirements [122]. Although glycolysis gener-
ates lower amounts of ATP, such is sufficient for the low 
bioenergy needs of quiescent HSCs. Studies suggest 
that maintaining mitochondrial health and low meta-
bolic activity is critical for HSC function, [123–125] 
and is tightly linked with the cell cycle state of quies-
cence [126]. Mitochondrial biosynthesis is stimulated 
in order to meet increased energy demands when tran-
sitioning from  G0 to  G1. Thus, the proliferation of HSCs 
is always associated with the glycolysis-to-OXPHOS 
metabolic switch, epigenetic landscape changes and 
increased production of ROS [124, 127–131]. ROS 
activate mitochondrial biosynthesis and protein trans-
lation by inducing the Akt-mTor-PGC-1α/β signaling 
pathway, which leads to HSC differentiation [132–138]. 
In addition, high levels of ROS cause irreversible dam-
age to mitochondria, lipids, proteins and DNA [139]. 
Much of the damage to mitochondria in HSCs is irre-
versible. Thus, HSCs employ several surveillance pro-
grams to maintain and/or restore their mitochondria 
and a low metabolic state in order to preserve their 
function. For example, the quality of mitochondria in 
HSCs is regulated by fission/fusion and mitophagy-
mediated mitochondrial quality control systems which 
segregate and remove the damaged mitochondria 
using lysosomal degradation [57, 140, 141]. However, 
if the damaged mitochondria cannot be fully removed, 
then HSCs will distribute the damaged mitochondria 
to one of the mitotic daughters in order to assure that 
the healthy mitochondria present in the other daugh-
ter cell will preserve the number and function of HSCs 
[98, 101, 102]. In addition, the signaling pathways 
which mediate nuclear-mitochondrial communica-
tion, including  NAD+-Sirt1-HIF-1α, Sirt7-NRF1 and 
Foxo/Sirt3-antioxidants (such as SOD2), also play criti-
cal roles in maintaining the low metabolic and inactive 
states of mitochondria by regulating redox reactions 
and the mitochondrial unfolding protein response 
(UPR) [124, 126, 129–131, 142, 143]. Genetic studies 
suggested that disruption of any of these quality control 
programs and signaling pathways in mitochondria will 
induce a premature aged phenotype in HSCs in ani-
mals [144]. Compared to young HSCs, down-regulation 
of Sirt1, Sirt3 and Sirt7 genes, reduced NAD levels, a 
decline in mitochondrial-encoded genes, and increased 
Akt-mTor signaling activity are detected in aged HSCs 
and are associated with increased mitochondrial pro-
tein folding stress, ROS levels and increased symmetric 
division. Finally, overexpression of Sirt3 or Sirt7, raising 
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nuclear  NAD+ levels or inhibition of either mTor or 
Cdc42, restore functionality to or even rejuvenate aged 
HSCs [101, 102, 135, 145, 146].
Epigenetic deregulation of HSCs during aging
Self-renewal and multipotency are sustained in HSCs 
by epigenetic machinery that allows for regulation of 
the epigenetic landscape, including DNA methylation 
patterns and histone methylation/acetylation profiles, 
through maintenance of self-renewal gene expression 
and repression of differentiation and lineage-determining 
genes [147–151]. The critical role of epigenetic regulators 
in promoting proper HSC function is well-documented 
in knockout and transgenic animal models [149, 150, 
152–154]. For example, Dnmt1 is a DNA methyltrans-
ferase enzyme which re-establishes existing DNA meth-
ylation patterns during cellular replication by recognizing 
hemi-methylated DNA and copying pre-existing DNA 
methylation marks from the parental template strand to 
the daughter strand [149]. Dnmt3a/3b acts as a de novo 
DNA methyltransferase which establishes the new DNA 
methylation patterns during development and stem cell 
differentiation [152, 155–157]. HSCs in mice decline in 
both number and function shortly after deletion of the 
Dnmt1 gene, [149, 150, 158] while HSCs are expanded 
with enhanced self-renewal in Dnmt3a-knockout mice 
and are further enhanced in Dnmt3a/3b double-knock-
outs [152, 156, 157]. Ten-eleven translocation (Tet) 
methylcytosine dioxygenases catalyze the hydroxyla-
tion of DNA 5-methylcytosine (5mC) to 5-hydroxym-
ethylcytosine (5hmC) [159]. Tet2 knockout promotes 
self-renewal and expansion of HSCs [160–163]. Poly-
comb repressor complex 1 (PRC1) and PRC2 repress the 
expression of target genes by deposition of the repressive 
marks  H2AK119ub [1] and  H3K27Me [3] [164, 165]. Mice 
with deletions of the key components of PRC1 or PRC2, 
such as Bmi, Ezh1 and Eed, experience HSC exhaustion 
[166–171]. The H3K4 demethylases Kdm5b (Jarid1b) and 
Kdm1a (Lsd1), as well as H3K27 demethylases Kdm6a 
(UTX) and H3K9 methyltransferase SUV39H1, also play 
essential roles in the regulation of HSC function [172–
175]. In addition, histone lysine acetyltransferases Kat6a 
(Moz), Kat6b (Morf ) and Kat8 (Mof) regulate target gene 
expression by depositing  H3K9ac,  H3K23ac/H3K14ac and 
 H4K16ac, respectively, on the regulatory regions of target 
genes. Genetic inactivation of any of these histone acetyl-
transferases causes HSC exhaustion in mice [176–179].
Accumulated evidence suggests that HSC aging is 
regulated by changes in the epigenetic landscape. Com-
parative studies of epigenetic profiling of young and aged 
HSCs reveal a number of epigenetic differences (age-
related epigenetic drift) that underlie the heterogeneous 
behavior, lineage-biased feature and clonal expansion 
of HSCs, as well as an increased risk of leukemic trans-
formation [159, 180, 181, 186, 187, 182]. Compared to 
young HSCs, there is generally a stable or slight global 
gain of DNA methylation and a reduction of 5-hmC in 
old HSCs [159, 183]. However, a substantial proportion 
of differentially altered DNA methylated regions (DMRs) 
in aged HSCs is associated with PRC2 target genes (with 
CpG islands), most of which are positive cell cycle regu-
lators and lineage determining factors. These include 
increased methylation on the genomic loci associated 
with lymphoid and erythroid lineages and reduced meth-
ylation on the genomic loci associated with the myeloid 
lineage [159]. Although such epigenetic alterations influ-
ence changes in gene expression that are associated with 
self-renewal and myeloid differentiation of aged HSCs, 
they contribute to an aging-related functional decline 
and myeloid differentiation skewing of aged HSCs by 
regulating gene expression in their differentiated progeny 
[71, 82, 184–186]. Compared to young HSCs, there is a 
reduction in  H4K16Ac levels and a more widespread dis-
tribution of  H3K4me [3] and  H3K27me [3] in aged HSCs 
[101]. Most importantly, the aging-related epigenetic 
changes of HSCs are associated with a proliferative his-
tory, suggesting a proliferation-driven epigenetic memory 
loss [184]. Proliferation drives HSC aging by triggering 
the switch of HSCs from dormancy and multipotency to 
cellular activation and lineage priming through inducing 
an epigenetic switch (for example, a switch from Ezh1-
to-Ezh2 PRC2), [82] downregulating DNA methylation 
regulators such as Dnmt1, Dnmt3b and 3 Tet enzymes, 
as well as key chromatin modulators such as Bmi, Suz12, 
Eed, Kat6b, Jarid1b, Suv39H1 and Sirt1 [82, 92, 148, 159, 
187]. In addition, mutations in epigenetic modifiers are 
frequently detected in healthy elderly individuals and 
these also contribute to epigenetic landscape changes 
and the physiological process of aging in HSCs [187]. 
Consistently, obvious changes in epigenetic chromatin 
modifications were detected in aged HSCs. The expres-
sion of the microRNA miR-125b, a regulator of HSCs, is 
reduced in aged HSCs in both human and mouse. miR-
125b represses the expression of histone methyltrans-
ferase SUV39H1 leading to a global reduction in  H3K9Me 
[3] and loss of heterochromatin structure. Overexpres-
sion of miR-125b and inhibition of SUV39H1 in young 
HSCs induces loss of B cell potential, [175] while inhibi-
tion of miR-125b and upregulation of SUV39H1 in old 
HSCs promotes B cell potential [175].
By comparing gene expression profiling, the DNA 
methylation landscape and histone modification pat-
terns in parallel within purified HSCs from old mice and 
young mice, Goodall’s lab found that there are not only 
more  H3K4me [3] peaks but also broader  H3K4me [3] 
peaks across HSC identity and self-renewal genes. Also 
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observed was an increase in DNA methylation at tran-
scription factor binding sites associated with differenti-
ation-promoting genes in aged HSCs. Gene expression 
profiling demonstrates reduced TGF-β signaling and 
increased rDNA expression/ribosome activity in aged 
HSCs. This study suggests that epigenetic changes in 
aged HSCs might reinforce self-renewal and antagonize 
differentiation [159]. The discrepancy between the results 
of this study and other studies might be due to the more 
purified state of HSCs that were used in the latter study. 
The reinforced self-renewal epigenetic landscape changes 
in aged HSCs suggested by this study might reflect the 
enhanced self-renewal potential of Plt-bi and My-bi 
HSCs observed in old animals, while the impaired self-
renewal and lineage-biased epigenetic changes in aged 
HSCs detected by other studies might be due to contami-
nation by functionally defective HSCs and MPPs during 
analysis.
Age‑related HSC niche changes
Although the Bala-HSCs in old mice express many mye-
loid and platelet genes, they retain normal lymphoid 
commitment potential when transplanted into a young 
BM microenvironment [31, 59, 188, 189]. Even some 
Plt-/My-bi HSCs regain lymphoid differentiation poten-
tial upon transplantation into young mice. These revers-
ibility features of aged HSCs in the BM niches of young 
recipients suggest that the Plt-/My-biased commitment 
of aged HSCs is largely stimulated by the niche environ-
ment. HSC niches also undergo aging-related structural 
and functional changes which induce inflammatory chal-
lenges to HSCs [72]. Therefore, we might be able to reju-
venate aged HSCs by improving niche cell function and 
repressing inflammation in BM [12, 190].
HSC niches in BM
HSC niches in BM are composed of multiple hematopoi-
etic and non-hematopoietic cells interacting in a com-
plex 3-dimensional architecture to support HSC function 
[191]. Three types of BM niches for HSCs have been 
described, these being designated the endosteal, [192–
195] arteriolar, [196] and sinusoid niches (Fig. 6) [54, 56, 
197, 198]. However, the specific localization of HSCs and 
their niches remain difficult to determine and so are still 
largely unknown [48, 54, 56, 192–203]. Endosteal niches 
are primarily composed of spider-shaped N-cadherin+ 
osteoblastic (SNO) cells together with an osteopontin-
rich extracellular matrix within endosteal tissue. SNO 
cells are a type of osteogenic mesenchymal stromal cell 
(MSC) which maintain the quiescent state of hibernat-
ing reserve HSCs and protect such HSCs from the lethal 
effects of cancer chemotherapy [193, 204]. Endosteal 
niches play such a role probably through Jagged 1-stim-












































Fig. 6 HSC niche regeneration. Type-H ECs in arteriolar niches are stimulated by Dll4-Notch signaling to produce angiocrine factors. Such factors 
stimulate angiogenesis and osteogenesis to generate endosteal/arteriolar niches during early development and maintain these niches into 
adulthood. In response to irradiation or chemically induced BM damage, HSCs produce angiopoietin I/VEGF and ECs express Jag2. Such factors 
collaboratively induce the regeneration of sinusoid niches by stimulating the production of angiocrine factors by type-H ECs. In old mouse BM, the 
endosteal/arteriolar niches are significantly restricted while the sinusoid niches show minimal changes
Page 12 of 22Zhang et al. J Hematol Oncol          (2020) 13:157 
proliferative repression in HSCs [192, 205–208]. In addi-
tion, lymphoid-bi-HSCs or B-cell progenitors might be 
primarily localized to osteoblastic niches. Osteoblas-
tic MSCs, together with perivascular BM MSCs, sup-
port B-lymphopoiesis by producing lymphocyte-specific 
cytokines such as Cxcl12 and IL-7 [209–213]. Further-
more, T-reg cells in endosteal niches provide an immune-
privileged microenvironment to protect HSCs from 
immune attack [214–216]. Both arteriolar and sinusoid 
niches are composed of vascular endothelial cells (ECs) 
and surrounding MSCs [197, 203, 217]. However, the ECs 
and MSCs in arteriolar and sinusoid niches are not the 
same based on their cell surface markers, gene expres-
sion patterns and cytokine profiles, suggesting that they 
are potentially functionally different [218]. For example, 
the ECs in arteriolar niches are VE-cadherin+CD31hig
hEmcnhighSca1+VEGFR2+VEGFR3−ephrin-B2+Sox17
+Neuropilin-1+ type-H ECs, while the ECs in sinusoid 
niches are VE-cadherin+CD31lowEmcnlowStab2highSca1−
VEGFR3−VEGFR2+ type-L ECs. The MSCs in arteriolar 
niches are  Lep R+​CD 140 αh igh Ne sti n-G FP bri ght NG 2-G FP 
bri ght Sc a1 +M yh1 1+SCFhighCxcl12+ osteo-biased MSCs, 
whereas MSCs in sinusoid niches are  Lep R+​CD 140 αh igh 
Ne sti n-G FP dim NG 2l ow Sca 1−​SCF+Cxcl12+ adipo-biased 
MSCs which are distributed throughout the BM [56, 196, 
198, 219–222]. Most arteriolar niches are primarily local-
ized in epiphyseal/metaphyseal BM and the endosteal 
region of diaphyseal BM, which might have certain over-
laps with endosteal niches. The type-H ECs in arteriolar 
niches regulate both angiogenesis and osteogenesis dur-
ing development. Kunisaki et  al. reported that in young 
adult BM, most quiescent HSCs are closely associated 
with arterioles. It was proposed that arteriolar niches are 
characterized by low oxygen concentration that helps to 
maintain quiescence in HSCs for hematopoietic preser-
vation, [198, 223] while sinusoid niches maintain their 
activated HSCs for active hematopoietic regeneration 
[196]. However, several recent studies suggested that 
both quiescent and activated HSCs are localized in sinu-
soid niches and are almost uniformly in contact with vas-
cular VE-cadherin+ ECs and  LepR+ MSCs [54, 56]. Such 
a discrepancy might be due to the different markers used 
to detect HSCs, which could have led to the selective 
investigation of different subsets of HSCs in the different 
studies.
In addition, macrophages (Mφ), megakaryocytes (MK) 
and sympathetic neurons have also been described 
as component cells of HSC niches.  CD169+, DARC/
CD234+ and/or αSMA+ Mφ are required for retain-
ing quiescent HSCs in  Nestin+ endosteal/arteriolar 
niches. Mφ play such a role by stimulating HSC niche 
chemokine/cytokine production, CD82-mediated signal-
ing, Cox2-PGE-2-dependent HSC survival and clearance 
of senescent  CD62LlowCXCR4high neutrophils [224–229]. 
Mφ depletion promotes HSC egress into the bloodstream 
[224–229]. Sympathetic nerves regulate HSC mobiliza-
tion and circadian oscillation release by stimulating β2 or 
β3  adrenergic receptors (AR) in BM MSCs and osteo-
blasts in collaboration with Mφs and neutrophils [230–
233]. Furthermore, MKs spatially associate with a subset 
of HSCs and maintain HSC quiescence in BM niches. 
MKs play such a role by producing TNF-βCXCL4 and 
thrombopoietin through collaborating with other niche 
cells such as non-myelinating Schwann cells. [16–18, 37, 
38] Further study has suggested that most  vWF+ Plt-/
My-bi HSCs are localized within sinusoid niches associ-
ated with MKs. MKs regulate the proliferation and HRC 
of  vWF+ Plt-/My-bi HSCs, while  NG2+ MSCs in arteri-
olar niches regulate quiescence and localization of  vWF− 
Ly/Bala-HSCs [104]. Depletion of MKs in the BM leads 
to the proliferation of dormant HSCs and expands Plt-/
My-bi HSCs [104].
Heterogeneity of BM MSCs and ECs
Like HSCs and HPCs, MSCs in BM are also a mixture of 
cell populations which are enriched for MSC-stem cells 
(MSC-SCs) and early progenitors for adipocytes, osteo-
blasts, chondrocytes, pericytes and fibroblasts as demon-
strated by cell surface markers, gene expression profiles 
and cytokine profile studies at single-cell resolution [234–
240]. Only a small proportion of specific MSCs function 
as HSCs niches. Such types of MSCs have been defined 
as Nestin-GFP+,  CD45−CD31−Sca1+CD24+, < 10% of 
 LepR+ or  Pdgfr+Sca1+CD51+ which have the ability to 
generate CFU-F and mesenspheres in in  vitro culture 
and can differentiate into all lineages of MSCs includ-
ing adipocytes, osteoblasts, chondrocytes, pericytes and 
fibroblasts both in vitro and in vivo, suggesting they are 
MSC-SCs [196, 203, 219, 241–249]. In addition, differ-
ent types of hematopoietic progenitors (HPCs) such as B 
lymphocyte progenitors and erythroid progenitors also 
have their unique niches formed by different types of 
MSCs, which produce lineage-instructive cytokines [211, 
250, 251]. These studies suggest that MSC-SCs produc-
ing self-renewal factors function as niche cells for HSCs, 
while distinct types of MSC-progenitors producing line-
age-specific factors function as niches for distinct types 
of HPCs. Most importantly, like HSCs, the MSC-SCs are 
also heterogeneous and might function as niches for dif-
ferent sub-types of HSCs [234, 252, 253]. In further sup-
port of this notion, it was found that Nestin-GFPbright and 
 Pdgfr+Sca1+CD51+ MSC-SCs promote HSC expansion 
in  vitro by producing the HSC niche-specific cytokines 
SCF (KitL), SDF1 (Cxcl12), IL7, angiopoietin 1 (angpt 1) 
and adhesive molecular Vcam1 [241, 243, 250]. This abil-
ity of MSC-SCs is attenuated upon differentiation and 
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can be restored by overexpression of 5 genes (Klf7, Ostf1, 
Xbp1, Irf3 and Irf7) which revitalize MSC-SCs [254].
The critical role of BM ECs in HSC regulation has been 
well documented. During conditions of homeostasis, spe-
cific types of BM ECs are required for maintaining HSCs 
by producing the key HSC-specific cytokines Cxcl12, 
SCF and Jagged 1/2. During hematopoietic regeneration 
and in vitro culture, BM ECs promote HSC expansion by 
producing soluble and membrane-bound angiocrine fac-
tors including SCF, BMP2/4, IGFBP2, CXCL12, Notch 
ligands, Wnt5a, EGF, and pleiotrophin [220, 255–265]. 
However, the stem cells and progenitors for ECs are not 
clearly identified. Whether there are EC-stem cells (EC-
SCs) that selectively function as niches for HSCs needs 
to be determined in the future [248, 249, 266]. A recent 
study found that  Apelin+ ECs represent 12.4% ± 1.3% of 
BM ECs [249, 267]. Such ECs are a subset of type-H arte-
riolar ECs that express niche factors, including connexin 
gap-junction proteins, Notch ligands, and pleiotrophin 
(PTN).  Apeln+ ECs are required for maintaining HSCs 
during steady-state hematopoiesis and regulate hemat-
opoietic regeneration in response to myeloablative injury 
[249]. It should be emphasized here that HSCs also pro-
duce factors to regulate their own niches. For example, 
HSCs produce VEGF-A and angiopoietin which induce 
vessel regeneration by stimulating Dll4-Notch signal-
ing in type-H ECs for sprouting angiogenesis and vas-
cular niche regeneration [218, 249]. In addition, type-H 
ECs also release angiocrine factors and osteogenic fac-
tors which promote proliferation and differentiation of 
osteo-MSC-SCs in endosteal/arteriolar niches for vascu-
larization and osteogenesis [218, 221, 249, 266, 268–275]. 
Thus, it is most likely the case that HSCs, MSC-SCs and 
EC-SCs are associated during differentiation and their 
progeny work together as niches for each other [276].
Aging of HSC niches
HSC niches in BM undergo significant structural and 
functional alterations during aging [277]. Compared 
to young mice, although overall vascular density is 
increased in BM tissue of aged mice, [221, 230] arter-
ies and arterioles are decreased in their length and 
diameter and the vessels in aged BM display a disor-
ganized orientation. In particular, the vessels contain-
ing type-H ECs that bridge the arteriolar and sinusoid 
capillaries are significantly reduced [278]. However, the 
sinusoid vasculature is less affected and small capillar-
ies containing type-L ECs (< 6 mm in diameter) in the 
central BM are expanded [190, 278]. The retraction of 
endosteal regions and reduced transitional zone ves-
sels in these regions, along with expanded small capil-
laries in the non-endosteal (central) region, suggest a 
reduction in endosteal/arteriolar niches with a reduced 
effect on sinusoid niches [190]. The age-related reduc-
tion in endosteal/arteriolar niches is associated with 
the downregulation of Notch ligands Dll1 and Dll4 in 
type-H ECs, suggesting aging-related impairment of 
Notch signaling in the arteriolar niche [236, 278, 279]. 
In addition, due to the lack of recovery of expression of 
the endothelial Notch ligand Jag2 after chemotherapy 
in old sinusoid ECs, such drug treatment causes long-
term hematopoietic disruption in the elderly owing to 
the attenuated recovery of sinusoidal niches [81, 278]. 
The results of these studies suggest that altered Notch 
signaling critically contributes to the aging-related 
defects of both endosteal/arteriolar and sinusoid niches 
of HSCs [81] (Fig. 7).
Consistent with structural changes in BM niches, 
the MSCs and ECs in old BM display significant 
qualitative and quantitative changes. Although the 
absolute numbers of BM MSCs and ECs are not sig-
nificantly altered, [280–284] the numbers of Nestin-
GFPbrightPDGFRβ+NG2+  MSCs and  CD31hiEmcnhigh 
type-H ECs in endosteal regions are reduced in the aged 
BM, while  LepR+Nestin-GFPlow MSCs and  CD31loEmcnlo 
type-L ECs in the central BM are not reduced [81, 190, 
230]. The qualitative changes of MSCs in older BM is 
demonstrated by: (1) reduced capacity of colony-forming 
unit fibroblasts (CFU-F) and mesenspheres in  vitro; (2) 
reduced expression of HSC niche factors; [230] and (3) 
reduced osteogenesis and increased adipogenesis that is 
associated with lower osteopontin secretion to the extra-
cellular matrix [194, 285]. As a consequence, an increase 
in adipocytes is a common feature of BM in the elderly 
and is associated with an increased risk of osteoporosis 
and bone fractures [247, 286, 287]. Most studies sug-
gested that adipocytes in the BM reduce hematopoietic 
reconstitution [286–288]. The aging-related contraction 
of endosteal BM and reduced osteopontin contained in 
the matrix in the elderly explain the myeloid skewing 
phenotype owing to the reduction in lymphocyte-specific 
niches [251, 289–292]. Supporting this idea, it was found 
that the decline in osteopontin accelerates HSC divisions 
during aging, and treatment with thrombin-cleaved oste-
opontin partially reverses the age-associated phenotype 
of HSCs [194, 254]. The aging-related structural changes 
of BM niches are also associated with functional declines 
of vascular ECs as demonstrated by decreased angiogenic 
potential. Thus, the vascular niche in old mice shows 
increased leakiness and ROS levels. In addition, ECs and 
MSCs isolated from older mice show reduced ability to 
support the expansion of LT-HSCs in co-culture com-
pared to their younger counterparts [293]. It was found 
that expression of Dll4 in vascular ECs prevents myeloid 
skewing of HSCs [236].
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Changes in HSC‑niche interactions during aging
More HSCs in aged mice are localized at some dis-
tance from the endosteal bone surface, arterioles, Nes-
tin-GFPhigh cells and/or MKs in  situ. However, HSC 
distance from sinusoids and Nestin-GFPlow cells appears 
unchanged [81, 190, 230]. Significantly more HSCs egress 
into the circulation in old mice [294]. Upon transplan-
tation, aged HSCs display homing defects which corre-
late with increased HSCs being localized away from the 
endosteum [101]. Long-term labeling retention assays 
demonstrate that the most quiescent LR-HSCs with the 
highest HRC and cellular polarity reside individually and 
predominantly in Nestin-GFPlow perisinusoidal niches in 
old mice. In contrast, the non-LR-HSCs are largely apo-
lar and were found more frequently in clusters, [278, 279] 
which are located significantly further away from the vas-
culature [18, 19]. These studies suggest that due to the 
contraction of endosteal/arteriolar niches during aging, 
perisinusoidal niches protect HSCs from aging stresses in 
the BM of aged mice [81].
In addition to MSCs and ECs, many other types of 
niche cells, including MKs, Mφ and sympathetic nerves, 
also undergo significant aging-related changes. For 
example, the numbers of MKs and Mφ are increased 
in the BM of old animals; however, the HSC support-
ive function of these cells has undergone decline in 
old BM. More HSCs in old animals are localized away 
from MKs [190, 230] The MKs in aged mice have abun-
dant pseudopodial extensions and fail to maintain HSC 
quiescence [190]. The aged BM Mφs display impaired 
ability to clear senescent neutrophils. In addition, aged 
BM Mφs cause elevated IL-1β and promote the expan-
sion of Plt-/My-bi HSCs at the expense of Bala-HSCs 
[295]. The response of BM MSCs to adrenergic sign-
aling is altered due to the switch of β3-AR to β2-AR 
expression. Such a signaling switch also contributes to 
HSC aging [296]. Furthermore, age-associated senes-
cent B cells (ABCs), myeloid-derived suppressor cells 
(MDSCs) and plasma cells are increased in old BM. 
Both MDSCs and ABCs produce elevated concentra-
tions of pre-inflammatory cytokines like CCL5, IL-1, 
TNFα and interferon-γ, whereas plasma cells induce 
the production of inflammatory factors from BM MSCs 
[297–301]. All of these inflammatory cells also contrib-
ute to enhanced myelopoiesis in aging BM [302].
Fig. 7 Mechanism of HSC aging. HSCs undergo niche-driven and proliferation-associated changes during aging. Proliferation induces multiple 
stresses on HSCs including replication, ribosome biosynthesis, DNA damage, as well as metabolic and epigenetic stresses. Such stresses attenuate 
the self-renewal capacity of HSCs by inducing p53-dependent/independent senescence/apoptosis and promote lineage-biased differentiation by 
inducing platelet/myeloid genes and repressing lymphoid genes. Aging of HSC niches promotes the switch from asymmetric division to symmetric 
division in HSCs and impairs the self-renewal of HSCs due to a reduction in key niche factors including SCF, Cxcl12, IL7, and Notch ligands. In 
addition, the accumulation of MKs, M, plasma cells (PCs), aging-associated B cells, and MDSCs, which is primed by inflammatory mediators, 
promotes the Plt/My-biased phenotype in HSCs through the production of inflammatory cytokines such as CCL5, IL1β, TNFα, IFN-γ, Wnt5 and TGFβ
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Conclusions
Significant progress has been made during the last 
30  years in the study of aging-related changes in HSCs 
and their niches. This progress includes: (1) development 
of reliable panels of antibody markers and genetic animal 
models for analysis of HSCs in both young and old mice; 
(2) improved ability for the examination of functional 
HSCs and determination of the heterogeneity of HSCs by 
using single-cell transplantation and single-cell sequenc-
ing; (3) improved ability to more precisely detect HSC 
localization in the BM and the structure/components 
of HSC niches through the use of deep imaging quanti-
fication and 3-dimensional microanatomical analysis of 
the BM niche [303]. Such technical improvements have 
allowed the examination of the age-dependent structural 
changes of HSC niches at the resolution of single cells; 
[221, 278] (4) investigation of the aging-associated accu-
mulation of several types of mature hematopoietic cells 
and how they impact HSC aging; and (5) identification 
of potential niche factors and signaling pathways that are 
associated with HSC aging [268]. All these achievements 
not only improve our ability to understand the cellular/
molecular mechanisms by which physiological aging of 
the hematopoietic/immunologic system is regulated, but 
will help us to elucidate the pathogenesis of aging-related 
hematopoietic disorders.
While all of these foregoing advances are significant, 
there are still many aspects of this topic that need to 
be further investigated. First, several conflicting results 
have been reported with regard to quiescent HSCs, 
active HSCs and their niches, owing to the different 
protocols that have been used in the identification of 
HSCs in  situ. For example, some studies used CD11b 
and CD41 in their lineage cocktails and thus excluded 
many of the aged HSCs, whereas others did not include 
these antibodies in their cocktails. Second, the conclu-
sions concerning aging-related changes in HSCs were 
not always consistent owing to the different standards 
of purity of HSCs and different pre-conditioning proto-
cols that were used for transplantation functional stud-
ies. For example, most research protocols use radiation 
for pre-conditioning recipient animals in preparation 
for HSC transplantation. However, it must be kept in 
mind that this induces significant inflammation and 
might preferentially stimulate the Plt/My-bi feature in 
the HSCs being studied. Several recent reported studies 
used busulfan or anti-Kit antibodies for pre-condition-
ing of recipient mice, resulting in minimal inflamma-
tion [189]. Compared to radiation, HSCs in recipients 
pre-conditioned by either of the latter two regimens 
are more balanced in multi-lineage engraftment [189]. 
Thus, in the future, the Plt-/My-bi feature of aged HSCs 
needs to be further verified using less inflammatory 
pre-conditioning assays in order to exclude the possi-
bility that this feature is induced by the inflammatory 
BM environment in recipients. In addition, different 
standards were used for evaluating LT-ML HRCs. For 
example, most previous studies examined only three 
lineages for engraftment, which failed to detect Plt-bi 
HSCs. Furthermore, several innate immune cells, such 
as B1 cells and ILC2P cells, accumulate in old mouse 
BM as well as in skin/intestinal tissues. Such cells were 
not considered in previous studies. Whether there are 
lineage-biased HSCs in BM specific for innate immune 
cells or not, and whether such HSCs are also increased 
in aged mice, need to be determined. Lastly, although 
the heterogeneity of both MSCs and ECs in BM tissue 
were investigated recently using a single-cell technique, 
the differentiation hierarchies of MSCs and ECs have 
not yet been determined. Taken together, the detailed 
cellular components and mechanisms of HSC niches 
have not been sufficiently elucidated.
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